REX AI Equity Premium Income ETF vs Regeneron Pharmaceuticals Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.35, while Regeneron Pharmaceuticals Inc trades at $795.62 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while REX AI Equity Premium Income ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | REGN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $812.27 |
52-Week Low | $32.45 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
AIPI (REX AI Equity Premium Income ETF) trades at $37.41 with minimal daily movement (+0.19%). The ETF employs an option-writing strategy focused on AI-related equities, generating substantial weekly dividends averaging $0.24-0.26 per distribution. Technical indicators show mixed signals with bullish moving averages but overbought RSI levels. The fund's unique structure provides high income but faces sustainability concerns if AI market momentum falters.
AIPI offers exceptional yield potential through its weekly distribution model but carries structural risks including potential NAV erosion. The ETF's performance depends heavily on continued AI sector strength and effective options management. Investors should weigh the high income against the fund's capped upside and concentration in technology stocks during market volatility.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Trailing returns across standard periods
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →